PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the painful rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.